

Liste complète des publications dans le domaine des PIDs ces 10 dernières années (2016-2026)

1^{er} ou dernier auteur

- 1) Lavis P, Garabet A, Kupper Cardozo A, **Bondue B**. The Fibroblast Activation Protein alpha as a biomarker of pulmonary fibrosis. Front Med (Lausanne). 2024 Sep 19;11:1393778. doi: 10.3389/fmed.2024.1393778.

[The fibroblast activation protein alpha as a biomarker of pulmonary fibrosis - PubMed](#)

- 2) El Kik A, Vander Kuylen M, Bailly B, Fallas J, **Bondue B**. Unusual cause of dyspnea in patient with Myelofibrosis: The Ruxolitinib lung. Respiratory Medicine Case Reports 2024; 51: 102090 doi: 10.1016/j.rmcr.2024.102090

[Unusual cause of dyspnea in patient with Myelofibrosis: The Ruxolitinib lung - PubMed](#)

- 3) **Bondue B**, Leduc D. Ablation endoscopique par micro-onde : une nouvelle alternative pour le traitement loco-régional des tumeurs pulmonaires malignes. Revue des Maladies Respiratoires 2024. doi: 10.1016/j.rmr.2024.02.004

[\[Electromagnetic navigation bronchoscopy guided micro-wave ablation: A new loco-regional therapy for pulmonary malignancy\] - PubMed](#)

- 4) Lavis P, Pingitore J, Doumont G, Garabet A, Van Simaey G, Lacroix S, Passon N, Van Heymbeek C, De Maeseneire C, Allard J, Collin A, Huaux F, Decaestecker C, Salmon I, Goldman S, Cardozo AK, **Bondue B**. Usefulness of FAP α assessment in bronchoalveolar lavage as a marker of fibrogenesis: results of a preclinical study and first report in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Oct 25;24(1):254. doi: 10.1186/s12931-023-02556-6.

<https://pmc.ncbi.nlm.nih.gov/articles/PMC10601150/>

- 5) Lavis P, Morra S, Orte Cano C, Albayrak N, Corbière V, Olislagers V, Dauby N, Del Marmol V, Marchant A, Decaestecker C, Mascart F, De Vos N, Van de Borne P, Salmon I, Rummelink M, Parmentier M, Cardozo AK, **Bondue B**. Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality. Front Immunol. 2022 Aug 12;13:941663. doi: 10.3389/fimmu.2022.941663.

[Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality - PubMed](#)

- 6) Wuyts WA, Dahlqvist C, Slabbynck H, Schlessers M, Gusbin N, Compere C, Maddens S, Rizzo S, Kirchgaessler KU, Bartley K, **Bondue B**. Quality of Life and Healthcare Resource Use in a Real- world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry. *Pulm Ther* 2022. <https://doi.org/10.1007/s41030-022-00187-8>

[Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry - PubMed](#)

- 7) Refaee T*, **Bondue B***, Van Simaey G, Wu G, Yan C, Woodruff H, Goldman S, Lambin P. A handcrafted radiomics-based model for the diagnosis of usual interstitial pneumonia in patients with idiopathic pulmonary fibrosis. *J Pers Med*. 2022 Feb 28;12(3):373. *: these authors contributed equally. DOI: 10.3390/jpm12030373

[A Handcrafted Radiomics-Based Model for the Diagnosis of Usual Interstitial Pneumonia in Patients with Idiopathic Pulmonary Fibrosis - PubMed](#)

- 8) **Bondue B**, Schlossmacher P, Allou N, Gazaille V, Taton O, Gevenois PA, Vanderghelyns F, Rimmelink M, Leduc D. Trans-bronchial lung cryobiopsy in patients at high-risk of complications. *BMC Pulm Med*. 2021 Apr 26;21(1):135. DOI: 10.1186/s12890-021-01503-9

[Trans-bronchial lung cryobiopsy in patients at high-risk of complications - PubMed](#)

- 9) Noure L, Küçük K, Simeni Njonnou SR, Del Marmol V, White J, **Bondue B**. Respiratory distress syndrome associated with erythrodermic psoriasis. *Case Rep Dermatol* 2021;13:83–88 DOI: 10.1159/000511368

[Respiratory Distress Syndrome Associated with Erythrodermic Psoriasis - PubMed](#)

- 10) **Bondue B**, Leduc D, Froidure A, Pieters P, Taton O, Heinen V, Alexander P, Hoton D, Dome F, Rimmelink M. Usefulness of Surgical Lung Biopsies after Cryobiopsies when Pathological Results Are Inconclusive or show a Pattern Suggestive of a Nonspecific Interstitial Pneumonia. *Respir Res*. 2020 Sep 4;21(1):231. DOI: 10.1186/s12931-020-01487-w

<https://pmc.ncbi.nlm.nih.gov/articles/PMC7487918/>

[Usefulness of surgical lung biopsies after cryobiopsies when pathological results are inconclusive or show a pattern suggestive of a nonspecific interstitial pneumonia - PubMed](#)

- 11) Froidure A, Pieters T, Leduc D, **Bondue B**. Bad performance of lung cryobiopsy in the diagnosis of interstitial lung diseases: don't throw the baby out with the bathwater. American Journal of Respiratory and Critical care. Letter to the editor. *Am J Respir Crit Care Med*. 2019;200(7):938-939. DOI: 10.1164/rccm.201903-0701LE

[Bad Performance of Lung Cryobiopsy in the Diagnosis of Interstitial Lung Diseases: Don't Throw the Baby Out with the Bathwater - PubMed](#)

- 12) Wuyts WA; Dahlqvist C; Slabbynck H; Schlessen M; Gusbin N; Compere C; Maddens S; Lee YC; Kirchgaessler KU; Bartley K; **Bondue B**. Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. *Respir Res* 2019;20(1):231. DOI: 10.1186/s12931-019-1182-z

[Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry - PubMed](#)

- 13) **Bondue B**, De Vuyst P, Leduc D. Cryobiopsies pulmonaires transbronchiques pour le diagnostic des pneumopathies interstitielles diffuses. *La Lettre du Pneumologue* 2019; Vol 22 - n°2: 82-86.

- 14) **Bondue B**, Castiaux A, Van Simaey G, Mathey C, Sherer F, Egrise D, Lacroix S, Huaux F, Doumont G, Goldman S. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients. *Respiratory Research* 2019; 20(1):10. doi: 10.1186/s12931-019-0974-5.

[Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients - PubMed](#)

<https://link.springer.com/article/10.1186/s12931-019-0974-5>

- 15) Wuyts W, Dahlqvist C, Slabbynck H, Schlessen M, Gusbin N, Compere C, Maddens S, Kirchgaessler K, Bartley K, **Bondue B** (2018). Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. *BMJ Open Respiratory Research; BMJ Open Resp Res* 2018;5:e000331 DOI: 10.1136/bmjresp-2018-000331

[Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry - PubMed](#)

- 16) Castiaux A, Van Simaey G, Goldman S, **Bondue B** (2018). Assessment of 18F-FDG uptake in idiopathic pulmonary fibrosis: influence of lung density changes. *Eur J Hybrid Imaging*. 2018; 2:27 <https://doi.org/10.1186/s41824-018-0045-z>

<https://link.springer.com/article/10.1186/s41824-018-0045-z>

- 17) **Bondue B**, Pieters T, Alexander P, De Vuyst P, Ruiz Patino M, Hoton D, Remmelink M, Leduc D (2017). Role of Transbronchial Lung Cryobiopsies in Diffuse Parenchymal Lung Diseases: Interest of a Sequential Approach. *Pulm Med*. 2017:6794343. DOI: 10.1155/2017/6794343

<https://pmc.ncbi.nlm.nih.gov/articles/PMC5415669/>

- 18) **Bondue B** (2015). Actualités dans la prise en charge des pathologies interstitielles diffuses. *Vaisseau-Coeur-Poumon*; 20 (6): 55-60.

- 19) **Bondue B**, Sherer F, Van Simaey G, Doumont G, Egrise D, Yakoub Y, Huaux F, Parmentier M, Rorive S, Sauvage S, Lacroix S, Vosters O, De Vuyst P, Goldman S (2015). PET-CT with ¹⁸F-FDG and ¹⁸F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis. *Journal of Nuclear Medicine* 56 (1): 127-132. DOI: 10.2967/jnumed.114.147421

[PET/CT with 18F-FDG- and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis - PubMed](#)

Co-auteur

- 1) Peter Janssens, MD, PhD^a, Heini Kanervo, RN^b, Ilse Meerschaut, MD, PhD^c, Eva Schoeters^d, Veronique Verplancke^e, Yves Sznajder^f, Anna C. Jansen^g, MD, PhD. On behalf of the **Belgian TSC Consensus Group**. Belgian Consensus Recommendations for Tuberous Sclerosis Complex. *In preparation 2026*

- 2) Protocole National de Diagnostic et de Soins (PNDS) 2026. Vascularites associées aux ANCA rédigé sous l'égide du :Groupe Français d'Etude des Vascularites et de la filière de santé des maladies auto-immunes et auto-inflammatoires rares (FAI²R). **F. Vandergheynst**

https://www.has-sante.fr/upload/docs/application/pdf/2026-02/pnds_vaa_janvier_2026_vf.pdf

- 3) Sahay S, Visovatti S, Tonelli AR, Villasmil Hernandez N, Austin ED, Badagliacca R, Berger RMF, Boucly A, Chen Y, Church C, Delcroix M, Everett AD, Farber HW, Fauvel C, Gomberg-Maitland M, Griffiths M, Haddad F, Han Y, Hemnes A, Hoeper MM, Kanwar MK, Lachant D, Murthy S, Olsson KM, Preston I, Rådegran G, Sitbon O, Trivieri MG, **Vachieri JL**, Vanderpool R, Weatherald J, White RJ, Whitford H, Wilson M, Benza RL. International Society for Heart and Lung Transplantation (ISHLT) Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension. *J Heart Lung Transplant*. 2025 Nov;44(11):e73-e131. doi: 10.1016/j.healun.2025.04.015.

<https://pubmed.ncbi.nlm.nih.gov/40910964/>

- 4) Richeldi L, Azuma A, Cottin V, Kreuter M, Maher TM, Martinez FJ, Oldham JM, Valenzuela C, Clerisme-Beaty E, Gordat M, Wachtlin D, Liu Y, Schlecker C, Stowasser S, Zoz DF, Wijsenbeek MS; **FIBRONEER-IPF Trial Investigators**. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis. *N Engl J Med*. 2025 Jun 12;392(22):2193-2202. doi: 10.1056/NEJMoa2414108. Epub 2025 May 18. PMID: 40387033. DOI: 10.1056/NEJMoa2414108

[Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis - PubMed](#)

- 5) Maher TM, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Richeldi L, Valenzuela C, Wijsenbeek MS, Clerisme-Beaty E, Coeck C, Gu H, Ritter I, Schlosser A, Stowasser S, Voss F, Weimann G, Zoz DF, Martinez FJ; **FIBRONEER-ILD Trial Investigators**. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. *N Engl J Med*. 2025 Jun 12;392(22):2203-2214. doi: 10.1056/NEJMoa2503643. Epub 2025 May 19. PMID: 40388329. DOI: 10.1056/NEJMoa2503643

[Nerandomilast in Patients with Progressive Pulmonary Fibrosis - PubMed](#)

-
- 6) Trapnell BC, Inoue Y, Bonella F, Wang T, McCarthy C, Arai T, Akasaka K, Mariani F, Mogulkoc N, Song JW, Baba T, Jouneau S, Numakura T, Öcal N, Mihaltan F, Ataya A, Bendstrup E, Campo I, Carey B, Arena R, Robinson B, Fleming R, Wasfi Y, Pratt R; **IMPALA-2 Trial Investigators**. Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis. *N Engl J Med*. 2025 Aug 21;393(8):764-773 DOI: 10.1056/NEJMoa2410542

[Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis - PubMed](#)

- 7) Allanore Y, Khanna D, Smith V, Aringer M, Hoffmann-Vold AM, Kuwana M, Merkel PA, Stock C, Sambevski S, Denton CP; **SENSCIS Trial Investigators**. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. *Rheumatology (Oxford)*. 2024 Mar 1;63(3):639-647. DOI: 10.1093/rheumatology/kead280

[Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease - PubMed](#)

- 8) Kapuczinski A, Demeulenaere N, Rossi C, **Bondue B**, Léon M. Hypereosinophilia Associated With Antisynthetase Syndrome With anti-Ro52/PL12 Co-Positivity: An Unusual Presentation. *Authorea*. September 02, 2024. DOI: 10.1002/ccr3.72096

[Hypereosinophilia Associated With Antisynthetase Syndrome With Anti-Ro52/PL12 Co-Positivity: An Unusual Presentation - PubMed](#)

- 9) Guirriec Y, Luque-Paz D, Bernard G, Mabo A, Kerjouan M, Ménard C, Monnier D, Nunes H, Uzunhan Y, Reynaud-Gaubert M, Bermudez J, Borie R, Crestani B, Traclet J, Wémeau-Stervinou L, Chenivresse C, Gomez E, Prévot G, Bourdin A, Bondue B, Bergeron A, Cottin V, Lederlin M, Jouneau S; OrphaLung network. Pulmonary fibrosis in patients with autoimmune pulmonary alveolar proteinosis: a retrospective nationwide cohort study. *ERJ Open Res*. 2024 Dec 2;10(6):00314-2024. doi: 10.1183/23120541.00314-2024.

[Pulmonary fibrosis in patients with autoimmune pulmonary alveolar proteinosis: a retrospective nationwide cohort study - PubMed](#)

- 10) Lavis P, **Bondue B**, Cardozo AK. The Dual Role of Chemerin in Lung Diseases. *Cells* 2024, 13, 171. <https://doi.org/10.3390/cells13020171>

[The Dual Role of Chemerin in Lung Diseases - PubMed](#)

- 11) Froidure A, **Bondue B**, Dahlqvist C, Guiot J, Gusbin N, Wirtz G, Brusselle G, Strens D, Slabbynck H, Wuyts WA. Clinical course of suspected familial and sporadic idiopathic pulmonary fibrosis: Data from the PROOF-Next registry. *Respirology*. 2023 Dec 20. doi: 10.1111/resp.14650.

[Clinical course of suspected familial and sporadic idiopathic pulmonary fibrosis: Data from the PROOF-Next registry - PubMed](#)

- 12) Valent P, Klion AD, **Roufosse F**, Simon D, Metzgeroth G, Leiferman KM, Schwaab J, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Hoermann G, Haferlach T, Moriggl R, George TI, Akin C, Bochner BS, Gotlib J, Reiter A, Horny HP, Arock M, Simon HU, Gleich GJ. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. *Allergy*. 2023 Jan;78(1):47-59. doi: 10.1111/all.15544.

<https://pubmed.ncbi.nlm.nih.gov/36207764/>

- 13) Mabo A, Borie R, Wemeau-Stervinou L, Uzunhan Y, Gomez E, Prevot G, Reynaud-Gaubert M, Traclet J, Bergot E, Cadranel J, Marchand-Adam S, Bergeron A, Blanchard E, **Bondue B**, Bonniaud P, Bourdin A, Burgel PR, Hirschi S, Marquette CH, Quétant S, Nunes H, Chenivresse C, Crestani B, Guirriec Y, Monnier D, Ménard C, Tattevin P, Cottin V, Luque Paz D, Jouneau S; OrphaLung Network. Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort. *Thorax*. 2023 Sep 27;thorax-2023-220040. doi: 10.1136/thorax-2023-220040.

[Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort - PubMed](#)

<https://thorax.bmj.com/content/79/1/68.full>

- 14) Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, Groenveld I, Helmer E, Jenkins RG, Milner J, Molenberghs G, Penninckx B, Randall MJ, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins TR, Wuyts WA, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek MS; **ISABELA 1 and 2 Investigators**. Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials. *JAMA*. 2023 May 9;329(18):1567-1578. DOI: 10.1001/jama.2023.5355

[Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials - PubMed](#)

- 15) Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, **Vachieri JL**, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J*. 2023 Jan 6;61(1):2200879. doi: 10.1183/13993003.00879-2022.

<https://pubmed.ncbi.nlm.nih.gov/36028254/>

- 16) Froidure A, **Bondue B**, Dahlqvist C, Guiot J, Gusbin N, Wirtz G, Joos G, Cataldo D, Strens D, Slabbynck H, Wuyts WA. Correlation of Broncho-Alveolar Lavage Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data from the Belgium-Luxembourg IPF registry. *Chest*. 2022 Sep 29:S0012-3692(22)03901-0. DOI: 10.1016/j.chest.2022.09.031

[Correlation of BAL Cell Count and Pulmonary Function Tests in the Era of Antifibrotics: Data From the Belgium-Luxembourg Idiopathic Pulmonary Fibrosis Registry - PubMed](#)

17) Taton O, **Bondue B**, Roufosse F. Hypereosinophilic syndromes. Book chapter published in Eosinophilic Lung Diseases: ERS Monograph. Eur Respir Monogr 2022; 95: 153-176 DOI: 10.2147/IDR.S417495

18) Philippot Q, Kannengiesser C, Debray MP, Gauvain C, Ba I, Margherita Vieri M, Anne Gondouin A, Jean-Marc Naccache JM, Martine Reynaud-Gaubert M, Uzunhan Y, **Bondue B**, Israël-Biet D, Dieudé P, Fourrage C, Lainey E, Manali E, Papiris S, Wemeau L, Hirschi S, Mal H, Nunes H, Schlemmer F, Blanchard E, Beier F, Cottin V, Crestani B, Borie R, on behalf of the OrphaLung networkGenetique. Interstitial lung diseases associated with mutations of poly(A)-specific ribonuclease: a multicenter retrospective study. Respirology. 2022 Mar;27(3):226-235. doi: 10.1111/resp.14195.

[Interstitial lung diseases associated with mutations of poly\(A\)-specific ribonuclease: A multicentre retrospective study - PubMed](#)

19) Justet A, Klay D, Porcher R, Cottin V, Ahmad K, Molina Molina M, Nunes H, Reynaud-Gaubert M, Naccache JM, Manali E, Froidure A, Jouneau S, Wemeau L, Andrejak C, Gondouin A, Hirschi S, Blanchard E, **Bondue B**, Bonniaud P, Tromeur C, Prévot G, Marchand-Adam S, Funke-Chambour M, Gamez AS, Ba I, Papiris S, Grutters J, Crestani B, Van Moorsel C, Kannengiesser C, Borie R; OrphaLung Network. Safety and efficacy of pirfenidone and nintedanib in patients with Idiopathic Pulmonary Fibrosis and carrying a telomere related gene mutation. Eur Respir J. 2020 Nov 19:2003198. DOI: 10.1183/13993003.03198-2020

[Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation - PubMed](#)

20) Rinciog C, Diamantopoulos A, Gentilini A, **Bondue B**, Dahlqvist C, Froidure A, Wuyts W, Soulard S. The Cost-Effectiveness of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium. *Pharmacoecon Open*. 2020 Jan 14. doi: 10.1007/s41669-019-00191-w. [Epub ahead of print]

[Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium - PubMed](#)

21) Terrier B, Charles P, Aumaître O, Belot A, Bonnotte B, Crabol Y, Durel CA, Ebbo M, Jourde-Chiche N, Lega JC, Puéchal X, Pugnet G, Quemeneur T, Ribl C, Samson M, **Vandergheynst F**, Guillevin L; French Vasculitis Study Group. ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance. Presse Med. 2020 Oct;49(3):104031. doi: 10.1016/j.lpm.2020.104031

<https://pubmed.ncbi.nlm.nih.gov/32645418/>

- 22) Wuyts W, Wijsenbeek M, **Bondue B**, Bouros D, Bresser P, Cordeiro C, Hilberg O, Magnusson J, Manali E, Morais A, Papiris S, Shaker S, Veltkamp M, Bendstrup E. Idiopathic pulmonary fibrosis: best practice in monitoring and managing a relentless fibrotic disease. *Respiration*. 2020;99(1):73-82. Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; **INBUILD trial investigators**. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet Respir Med*. 2020 May;8(5):453-460. DOI: 10.1016/S2213-2600(20)30036-9

[Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial - PubMed](#)

- 23) Moor C; Wijsenbeek M, Balestro E, Biondini D, Bondue B, Cottin V, Flewett R, Galvin L, Jones S, Molina-Molina Maria, Planas-Cerezales Lurdes, Prasse A, Prosch H, Russell A-M, Viegas M, Wanke G, Wuyts W, Kreuter M, Bonella F. Gaps in care of patients living with pulmonary fibrosis: An Expert Statement on the results of a Europe-wide survey. *ERJ Open Research* 2019 5: 00124-2019; DOI: 10.1183/23120541.00124-2019.

[Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey - PubMed](#)

- 24) Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG; **INMARK trial investigators**. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. *Lancet Respir Med*. 2019 Sep;7(9):771-779. DOI: 10.1016/S2213-2600(19)30255-3

[Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib \(INMARK study\): a randomised, placebo-controlled study - PubMed](#)

- 25) Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; **SENSCIS Trial Investigators**. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. *N Engl J Med*. 2019 Jun 27;380(26):2518-2528. DOI: 10.1056/NEJMoa1903076

[Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease - PubMed](#)

- 26) Kolb M, **Bondue B**, Pesci A, Miyazaki Y, Song JW, Bhatt NY, Huggins JT, Oldham JM, Padilla ML, Roman J, Shapera S. Acute exacerbations of progressive-fibrosing interstitial lung diseases. *Eur Respir Rev*. 2018 Dec 21;27(150). pii: 180071. DOI:

[Acute exacerbations of progressive-fibrosing interstitial lung diseases - PubMed](#)

- 27) Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; **INSTAGE Investigators**. Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. *NEngl J Med*. 2018 Nov 1;379(18):1722-1731. DOI:10.1056/NEJMoa1811737

[Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis - PubMed](#)

- 28) Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, Tomassetti S, Ryu JH, Fruchter O, Piciucchi S, Dubini A, Cavazza A, Chilosi M, Sverzellati N, Valeyre D, **Leduc D**, Walsh SLF, Gasparini S, Hetzel M, Hagmeyer L, Haentschel M, Eberhardt R, Darwiche K, Yarmus LB, Torrego A, Krishna G, Shah PL, Annema JT, Herth FJF, Poletti V. Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. *Respiration*. 2018;95(3):188-200. doi: 10.1159/000484055.

<https://pubmed.ncbi.nlm.nih.gov/29316560/>

- 29) D. Castillo, S. Walsh, DM. Hansell, M. Vasakova, V. Cottin, G. Altinisik, S. Palmucci, M. Sterclova, S. Harari, L. Richeldi, C. Vancheri, AU Wells; **ERICE ILD working group**. Validation of multidisciplinary diagnosis in IPF. *Lancet Respir Med*. 2018 Feb;6(2):88-89. doi: 10.1016/S2213-2600(18)30023-7.

[Validation of multidisciplinary diagnosis in IPF - PubMed](#)

- 30) P. De Vuyst, P. Dumortier, M. Remmelink, J. Thimpont, **B. Bondue**, P.A. Gevenois. Asbestosis or idiopathic pulmonary fibrosis? *La Lettre du Pneumologue* • Vol. XX - n° 5 - septembre-octobre 2017

- 31) Johansson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M; **Erice ILD Working Group**. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? *Lancet Respir Med*. 2017 Jul;5(7):591-598. doi: 10.1016/S2213-2600(17)30219-9.

[Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers? - PubMed](#)

- 32) J. Guiot, I. Struman, M. Chavez, M. Henket, M. Herzog, K. Scoubeau, N. Hardat, **B. Bondue**, JL. Corhay, C. Moermans, R. Louis (2017). Altered epigenetic features in

circulating nucleosomes in idiopathic pulmonary fibrosis. *Clinical Epigenetics*, accepted 9:84 DOI 10.1186/s13148-017-0383-x

[Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis - PubMed](#)

33) J. Guiot, **B. Bondue**, M. Henket, JL Corhay, R. Louis (2016). Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis; *BMC Pulm Med* 2016 May 23;16(1):86. DOI: 10.1186/s12890-016-0249-6

[Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis - PubMed](#)